Fedratinib for patients with myelofibrosis
- PMID: 40174995
- DOI: 10.1016/S2352-3026(24)00399-5
Fedratinib for patients with myelofibrosis
Conflict of interest statement
ST is an employee of the University Cancer Institute of Toulouse; receives consultancy fees from Novartis, Abionyx, Pharma, and CSL-Vifor; and is on advisory boards for Novartis, CSL-Vifor, GSK, Sanofi, and Alexion. JB is an employee of the University Hospital of Toulouse and receives consultancy fees from Astellas, Sandoz, CSL-Vifor, Sanofi, Congrès Colloques Convention, and AstraZeneca. All other authors declare no competing interests.
Comment on
-
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.Lancet Haematol. 2024 Oct;11(10):e729-e740. doi: 10.1016/S2352-3026(24)00212-6. Epub 2024 Sep 9. Lancet Haematol. 2024. PMID: 39265613 Clinical Trial.